CORCEPT THERAPEUTICS INC (CORT)
US2183521028 - Common Stock
CORT gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 203 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making CORT a very profitable company, without any liquidiy or solvency issues. CORT is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, CORT could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
CORT had positive earnings in the past year.
CORT had a positive operating cash flow in the past year.
CORT had positive earnings in each of the past 5 years.
Each year in the past 5 years CORT had a positive operating cash flow.
1.2 Ratios
CORT has a better Return On Assets (15.39%) than 95.07% of its industry peers.
Looking at the Return On Equity, with a value of 19.80%, CORT belongs to the top of the industry, outperforming 91.63% of the companies in the same industry.
CORT has a Return On Invested Capital of 18.44%. This is amongst the best in the industry. CORT outperforms 94.09% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CORT is significantly above the industry average of 16.81%.
The last Return On Invested Capital (18.44%) for CORT is well below the 3 year average (23.51%), which needs to be investigated, but indicates that CORT had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.39% | ||
| ROE | 19.8% | ||
| ROIC | 18.44% |
ROA(3y)20.82%
ROA(5y)21.9%
ROE(3y)23.47%
ROE(5y)24.62%
ROIC(3y)23.51%
ROIC(5y)25.15%
1.3 Margins
Looking at the Profit Margin, with a value of 20.31%, CORT belongs to the top of the industry, outperforming 94.58% of the companies in the same industry.
CORT's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 21.82%, CORT belongs to the best of the industry, outperforming 89.66% of the companies in the same industry.
In the last couple of years the Operating Margin of CORT has declined.
CORT has a Gross Margin of 98.64%. This is amongst the best in the industry. CORT outperforms 97.04% of its industry peers.
In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.82% | ||
| PM (TTM) | 20.31% | ||
| GM | 98.64% |
OM growth 3Y-8.36%
OM growth 5Y-3.35%
PM growth 3Y-6.37%
PM growth 5Y-20.83%
GM growth 3Y0.15%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
CORT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
CORT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CORT has more shares outstanding
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 15.21 indicates that CORT is not in any danger for bankruptcy at the moment.
CORT's Altman-Z score of 15.21 is amongst the best of the industry. CORT outperforms 91.63% of its industry peers.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.21 |
ROIC/WACC1.99
WACC9.25%
2.3 Liquidity
A Current Ratio of 3.54 indicates that CORT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.54, CORT is in line with its industry, outperforming 50.25% of the companies in the same industry.
CORT has a Quick Ratio of 3.48. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
CORT has a Quick ratio (3.48) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
The earnings per share for CORT have decreased strongly by -19.00% in the last year.
The Earnings Per Share has been growing by 15.94% on average over the past years. This is quite good.
CORT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.20%.
Measured over the past years, CORT shows a very strong growth in Revenue. The Revenue has been growing by 20.35% on average per year.
EPS 1Y (TTM)-19%
EPS 3Y4.1%
EPS 5Y15.94%
EPS growth Q2Q-6.67%
Revenue 1Y (TTM)13.2%
Revenue growth 3Y9.45%
Revenue growth 5Y20.35%
Revenue growth Q2Q21.53%
3.2 Future
CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.26% yearly.
CORT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.07% yearly.
EPS Next Y6.25%
EPS Next 2Y3.82%
EPS Next 3Y18.68%
EPS Next 5Y23.26%
Revenue Next Year17.56%
Revenue Next 2Y15.13%
Revenue Next 3Y14.37%
Revenue Next 5Y15.07%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 33.57, CORT can be considered very expensive at the moment.
Based on the Price/Earnings ratio, CORT is valued cheaply inside the industry as 81.28% of the companies are valued more expensively.
CORT's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.54.
Based on the Price/Forward Earnings ratio of 28.66, the valuation of CORT can be described as expensive.
CORT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 79.80% of the companies in the same industry.
CORT's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 20.22.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.57 | ||
| Fwd PE | 28.66 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CORT is valued a bit cheaper than the industry average as 79.31% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CORT indicates a rather cheap valuation: CORT is cheaper than 84.73% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.14 | ||
| EV/EBITDA | 21.61 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CORT does not grow enough to justify the current Price/Earnings ratio.
CORT has an outstanding profitability rating, which may justify a higher PE ratio.
CORT's earnings are expected to grow with 18.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)5.37
PEG (5Y)2.11
EPS Next 2Y3.82%
EPS Next 3Y18.68%
5. Dividend
5.1 Amount
No dividends for CORT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CORCEPT THERAPEUTICS INC
NASDAQ:CORT (12/11/2023, 3:30:00 PM)
After market: 27.19 0 (0%)27.19
+0.65 (+2.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.80B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.57 | ||
| Fwd PE | 28.66 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)5.37
PEG (5Y)2.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.39% | ||
| ROE | 19.8% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 21.82% | ||
| PM (TTM) | 20.31% | ||
| GM | 98.64% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-19%
EPS 3Y4.1%
EPS 5Y
EPS growth Q2Q
EPS Next Y6.25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)13.2%
Revenue growth 3Y9.45%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y